A Randomized Controlled Study on the Clinical Efficacy of Ginkgo Biloba Combined with Nicorandil in Patients with HFmrEF

• DOI: 10.1536/ihj.24-316
• Publication Date: 2025-01-30T22:14:03Z
• Authors: Xiang Gao; Fangyuan Liu; Xiaozhen Han; Shan Tang; Dingding Shen; Jia Zhang; Chuanliang Liu
• Keywords: Nicorandil

This study aimed to explore the clinical efficacy of Ginkgo biloba combined with Nicorandil in patients heart failure who have a mild decrease ejection fraction (HFmrEF).A total 316 HFmrEF were selected and randomly assigned either control group or combination group, each consisting 158 patients. The received standard secondary preventive treatment, while oral based on stable conventional treatment. Both groups treated continuously for six months. age, sex, body mass index (BMI), New York Heart Association cardiac function classification, history coronary disease, hypertension, diabetes, atrial fibrillation, smoking, left ventricular fractions (LVEF), rate, glycosylated hemoglobin (HbA1c), drug use two recorded. endpoints BMI, blood lipid levels, fasting glucose, renal function, HbA1c, N-terminal pro-brain natriuretic peptide (NT-proBNP), LVEF, cardiopulmonary exercise testing parameters, 6-minute walking distance (6MWD), Kansas City Cardiomyopathy Questionnaire (KCCQ) score after months incidence adverse reactions was recorded.After NT-proBNP, low-density lipoprotein cholesterol, triglyceride, creatinine, HbA1c levels lower than those (P < 0.05). high-density VO2peak, oxygen uptake efficiency slope, 6MWD, KCCQ scores higher There no statistically significant difference between > 0.05) hypotension, hypoglycemia, hypokalemia, headache, hospitalization due worsening failure.Ginkgo can effectively improve glucose tolerance, health-related quality life HFmrEF. Because there reactions, they be safely used.